Literature DB >> 19105507

Prophylaxis of bleeding episodes in patients with von Willebrand's disease.

Augusto B Federici1.   

Abstract

Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day. Finally, there are children who have epistaxis frequently and severely enough to cause anaemia. In these frequent and severe bleeders, the optimal therapy may be secondary long-term prophylaxis with von Willebrand factor (VWF)/FVIII concentrates rather than on-demand treatment on the occasion of bleeding episodes. The largest experience on such prophylaxis in VWD has been in Sweden in 35 patients with severe forms of VWD. Long-term prophylaxis was also implemented in a cohort of Italian patients with VWD: prophylaxis was used in seven patients with types 3 (n = 1 ), 2A (n = 4), 2M (n = 1) and type 1 (n = 1) VWD because of recurrent gastrointestinal bleeds and in four patients with type 3 VWD because of joint bleeds. Prophylaxis prevented bleeding completely in eight patients and largely reduced hospitalisation for blood transfusions in the remaining three. The cost-effectiveness of these prophylaxis regimens versus on-demand therapy will now be investigated in one large international study

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19105507      PMCID: PMC2652221          DOI: 10.2450/2008.0034-08

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  29 in total

1.  Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.

Authors:  A Dobrkovska; U Krzensk; J R Chediak
Journal:  Haemophilia       Date:  1998       Impact factor: 4.287

2.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).

Authors:  A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

3.  The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.

Authors:  F Rodeghiero; G Castaman; A Tosetto; J Batlle; F Baudo; A Cappelletti; P Casana; N De Bosch; J C J Eikenboom; A B Federici; S Lethagen; S Linari; A Srivastava
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

Review 4.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

Review 5.  Long-term prophylaxis in von Willebrand disease.

Authors:  Erik Berntorp; Pia Petrini
Journal:  Blood Coagul Fibrinolysis       Date:  2005-04       Impact factor: 1.276

Review 6.  Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.

Authors:  Augusto B Federici
Journal:  Blood Coagul Fibrinolysis       Date:  2005-04       Impact factor: 1.276

7.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

8.  The 80th anniversary of von Willebrand's disease: history, management and research.

Authors:  A B Federici; E Berntorp; C A Lee
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287

9.  The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.

Authors:  Augusto B Federici; Elena Santagostino; Maria Grazia Rumi; Antonio Russo; Maria Elisa Mancuso; Roberta Soffredini; Pier M Mannucci; Massimo Colombo
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

10.  Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.

Authors:  Augusto B Federici; Giancarlo Castaman; Massimo Franchini; Massimo Morfini; Ezio Zanon; Antonio Coppola; Annarita Tagliaferri; Elio Boeri; Maria Gabriella Mazzucconi; Gina Rossetti; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

View more
  5 in total

1.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

Review 2.  Continuing education course #2: current understanding of hemostasis.

Authors:  Andrew J Gale
Journal:  Toxicol Pathol       Date:  2010-11-30       Impact factor: 1.902

3.  Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A.

Authors:  S L Sood; A Cuker; C Wang; A D Metjian; E Y Chiang; J M Soucie; B A Konkle
Journal:  Haemophilia       Date:  2013-03-28       Impact factor: 4.287

4.  Development of an Optical Method for the Evaluation of Whole Blood Coagulation.

Authors:  Marinos Louka; Efstathios Kaliviotis
Journal:  Biosensors (Basel)       Date:  2021-04-09

5.  von Willebrand's disease: a report from a meeting in the Åland islands.

Authors:  E Berntorp; I Peake; U Budde; M Laffan; R Montgomery; J Windyga; A Goodeve; P Petrini; M von Depka; W Miesbach; D Lillicrap; A B Federici; R Lassila; G White
Journal:  Haemophilia       Date:  2012-09       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.